News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CytRx Corporation (CYTR)’s Aldoxorubicin Clinical Data Selected for Presentation at Preeminent Sarcoma Conference



9/7/2012 10:23:28 AM

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that favorable results from a Phase 1b/2 clinical trial with aldoxorubicin (formerly INNO-206) in patients with advanced soft tissue sarcoma will be featured in a poster and discussion presentation at the Connective Tissue Oncology Society (CTOS) 17th Annual Meeting on November 15 in Prague, Czech Republic

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES